Urgent.News

600+ sources. One page. See who else covered it.

Editions

Business

The Risky Business of Experimental Peptides

Business owners and politicians are lobbying regulators for easier access to new injectable drugs against the recommendations of some medical experts. But customer demand isn’t waning.

The Risky Business of Experimental Peptides

We haven't written up this one. Business of Fashion has the full story — the link below goes straight to it.

Read the original at businessoffashion.com →

More in Business

Nielsen's $2 billion DoubleVerify acquisition is a big play for CMOs

Nielsen is looking to broaden its advertiser-direct relationships and push further into helping CMOs plan and allocate their media budgets.

  • Nielsen acquires DoubleVerify for $2.15 billion to enhance advertising data reliability.
  • Acquisition consolidates audience measurement and ad verification under Nielsen.
  • Critics warn of potential conflicts of interest and reduced market competition.

More from Wednesday 12 August →